Clincosm LogoSign in Get a demo

Standardized Diagnosis and Treatment of Endocrine Hypertension

Sponsor
Affiliated Hospital of Nantong University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05149781
Collaborator
(none)
200
Enrollment
1
Location
35
Anticipated Duration (Months)
5.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Cases of endocrine hypertension or primary hypertension who have signed informed consent will be collected. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. A database will be established for all patients. The investigators will comprehensively evaluate the general conditions, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Clinical data and specimen will be collected.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Standardized diagnosis and treatment

Detailed Description

The investigators will collect 100 patients with secretory hypertension and 100 patients with essential hypertension. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. Resected specimens from surgical patients will be used for immunohistochemistry and western blot. A database will be established for all patients to assess their general situation, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors, etc. The investigators expect to find more accurate screening indicators from blood and urine specimens. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Blood pressure, degree of atherosclerosis, biochemical markers, hormone levels and cardiac function indicators will be measured at three time points.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Standardized Diagnosis and Treatment of Endocrine Hypertension
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
patients with EH

patients with endocrine hypertension

Procedure: Standardized diagnosis and treatment
Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
Other Names:
  • antihypertensive drugs

    		•
    patients with PH

    patients with primary hypertension

    Outcome Measures

    Primary Outcome Measures

    1. The control rate of blood pressure [12 months]

      The investigators will compare the proportion of patients with blood pressure below 140/90 mmHg after different treatments.

    Secondary Outcome Measures

    1. Changes of carotid imima-media thickness [12 months]

      Carotid ultrasound will be used to observe the changes of carotid intima-media thickness after different treatments.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    ageā‰„18 years

    Exclusion Criteria:

    1. myocardial infarction

    2. congestive heart failure

    3. stroke

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Gu Yunjuan Nantong Jiangsu China 226001

    Sponsors and Collaborators

    • Affiliated Hospital of Nantong University

    Investigators

    • Principal Investigator: Gu Yunjuan, M.D/Ph.D, Affiliated Hospital of Nantong University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Affiliated Hospital of Nantong University
    ClinicalTrials.gov Identifier:
    NCT05149781
    Other Study ID Numbers:
    • 1
    First Posted:
    Dec 8, 2021
    Last Update Posted:
    Jan 3, 2022
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Hypertension
    Antihypertensive Agents

    Study Results

    No Results Posted as of Jan 3, 2022